Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TK2 | O00142 | 6/20 | 0.55 |
| ▸ | TK1 | P04183 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TYMP | P19971 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496425 | 1.00 | HPGD (0.55) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL591657 | 0.95 | TK1 (0.56) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL2497466 | 0.93 | TK2 (0.56) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL15110503 | 0.89 | TK2 (0.60) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL26779948 | 0.84 | TK1 (0.60) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL5025556 | 0.83 | TK2 (0.55) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL20012371 | 0.83 | TK2 (0.55) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL13261412 | 0.83 | TK1 (0.62) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL20743084 | 0.83 | TK2 (0.55) | HPGDTK2TK1MAPK1TYMP | |
| SCHEMBL8301264 | 0.83 | TYMP (0.56) | HPGDTK2TK1MAPK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | HPGD 3278/4885TK2 2036/4885TK1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.